IL326531A - Cap analogs and methods of use thereof - Google Patents

Cap analogs and methods of use thereof

Info

Publication number
IL326531A
IL326531A IL326531A IL32653126A IL326531A IL 326531 A IL326531 A IL 326531A IL 326531 A IL326531 A IL 326531A IL 32653126 A IL32653126 A IL 32653126A IL 326531 A IL326531 A IL 326531A
Authority
IL
Israel
Prior art keywords
substituted
unsubstituted
nhc
nhnh2
heterocycloalkyl
Prior art date
Application number
IL326531A
Other languages
English (en)
Hebrew (he)
Inventor
Chunping Xu
Chanfeng Zhao
Alexandre V Lebedev
Ilya Vladimirovich ILICHEV
Hengyuan Lang
Original Assignee
Trilink Biotechnologies Llc
Chunping Xu
Chanfeng Zhao
Alexandre V Lebedev
Ilya Vladimirovich ILICHEV
Hengyuan Lang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trilink Biotechnologies Llc, Chunping Xu, Chanfeng Zhao, Alexandre V Lebedev, Ilya Vladimirovich ILICHEV, Hengyuan Lang filed Critical Trilink Biotechnologies Llc
Publication of IL326531A publication Critical patent/IL326531A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL326531A 2023-09-06 2024-09-06 Cap analogs and methods of use thereof IL326531A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363536844P 2023-09-06 2023-09-06
PCT/US2024/045502 WO2025054401A2 (en) 2023-09-06 2024-09-06 Cap analogs and methods of use thereof

Publications (1)

Publication Number Publication Date
IL326531A true IL326531A (en) 2026-04-01

Family

ID=92895771

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326531A IL326531A (en) 2023-09-06 2024-09-06 Cap analogs and methods of use thereof

Country Status (7)

Country Link
EP (1) EP4774281A2 (de)
KR (1) KR20260065838A (de)
CN (1) CN121794279A (de)
AU (1) AU2024337685A1 (de)
IL (1) IL326531A (de)
TW (1) TW202526022A (de)
WO (1) WO2025054401A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026010855A1 (en) 2024-07-02 2026-01-08 Trilink Biotechnologies, Llc Modified rna for increasing protein expression
US20260185136A1 (en) * 2024-12-27 2026-07-02 Eisai R&D Management Co., Ltd. 5'-cap modifications of rna

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1163251A1 (de) 1999-03-24 2001-12-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES N-acylphosphoramiditen und ihre verwendung in oligonukleotidsynthesen
JP5558811B2 (ja) 2006-06-01 2014-07-23 トリリンク バイオテクノロジーズ 核酸増幅のための化学的に修飾されたオリゴヌクレオチドプライマー
DK4276189T3 (da) * 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
PL248416B1 (pl) * 2020-02-12 2025-12-08 Explorna Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
CN118490818A (zh) * 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
CN116368226A (zh) * 2020-09-04 2023-06-30 维乎医疗有限公司 用于加帽rna的组合物和方法
KR20220140140A (ko) * 2021-04-09 2022-10-18 한미정밀화학주식회사 캡핑된 올리고뉴클레오티드 프라이머 및 이의 용도
US20240327444A1 (en) * 2021-07-05 2024-10-03 Japan Science And Technology Agency Method for Purifying Nucleotides, Device for Purifying Nucleotides, Hy-Drophobic Reagent, and Hydrophobic Substrate
US20250122546A1 (en) * 2021-10-28 2025-04-17 BioNTech SE Rna constructs and uses thereof
WO2023167880A2 (en) * 2022-03-01 2023-09-07 Verve Therapeutics, Inc. Compositions and methods for capping rnas

Also Published As

Publication number Publication date
TW202526022A (zh) 2025-07-01
WO2025054401A2 (en) 2025-03-13
WO2025054401A3 (en) 2025-05-08
AU2024337685A1 (en) 2026-02-26
EP4774281A2 (de) 2026-07-15
KR20260065838A (ko) 2026-05-11
CN121794279A (zh) 2026-04-03

Similar Documents

Publication Publication Date Title
IL314442A (en) Trinucleotide cap analogs and methods of using them
IL287720A (en) modulators of thr-in the cell and methods of using them
EP4031666A4 (de) Cap-guides und ihre verwendung für rna-mapping
IL289464A (en) Relaxin analogs and methods of using them
IL292810A (en) Therapeutic compounds and methods of use
IL294214B2 (en) Cyclic compounds and methods of using same
IL314320A (en) Compounds and methods of use
IL284670A (en) A mixture of peptide ingredients for skin regeneration and healing and its use
HUE066717T2 (hu) Cot modulátorok és eljárások alkalmazásukra
GB2613900B (en) Novel compounds and methods of use thereof
IL310096A (en) CD38 modulators and methods of using them
PT3958889T (pt) Composições de péptidos miméticos de colagénio para o tratamento de uma doença ou perturbação ocular so segmento posterior que envolve a retina, os vasos sanguíneos da retina, os nervos retinianos ou o nervo ótico
IL318393A (en) Azaquinazoline compounds and methods of use
ZA202207188B (en) Liquid tasimelteon formulations and methods of use thereof
PT4200018T (pt) Anticorpos anti-par-2 e métodos de uso dos mesmos
IL315862A (en) Angiotensinogen modulators and methods of using them
GB2589398B (en) Compounds and methods of use
IL314277A (en) Anti-B7-H3 compounds and methods of use
IL311999A (en) New modulators of EHMT1 and EHMT2 and their therapeutic use
IL310868A (en) Variants of interleukin-12 and methods of their use
GB202119051D0 (en) Wingsail and method of use
CA3301528A1 (en) Cap analogs and methods of use thereof
ZA202103193B (en) Single-dose use of a composition comprising a particular mixture of grape extract and blueberry extract
CA3267132A1 (en) ANTIBODIES DIRECTED AGAINST FENTANYL AND ITS ANALOGUES AND THEIR METHODS OF USE
LT4554562T (lt) Olanzapino kompozicijos ir panaudojimo būdai